SINGAPORE, SINGAPORE--(Marketwire - March 02, 2010) - Zecotek Photonics Inc. (TSX VENTURE: ZMS)(FRANKFURT: W1I) a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that Chile's prestigious Universidad Tecnica Federico Santa Maria, Valparaiso, Chile, has ordered the Company's proprietary third generation Micro-pixel Avalanche Photo Diode (MAPD-3N) for use in high-precision calorimeters for its participation in CERN's NA-61 experiments. The Universidad Tecnica Federico Santa Maria has an internationally recognized program in high energy physics, and participates in two experiments at the European Organization for Nuclear Research (CERN) in Switzerland, one experiment at the Fermi National Accelerator Laboratory, and two experiments at the Thomas Jefferson National Accelerator Facility in the United States. The High Energy Physics Program is building a new detector laboratory in Chile through funds from the Valparaiso Center for Science and Technology, which is led by Professor Ivan Schmidt. This Center has been recently selected by the Chilean Government as a "Center of Excellence", through their BASAL Program.
"Zecotek's solid-state MAPDs are an optimal choice for research in high energy physics at the NA-61 experiments," said Professor Ivan Schmidt. "Our research requires a detailed read out of scintillating fibers with significant quantum efficiency and fast timing in a very compact package. In the near future our group plans to develop other applications in high energy physics and in PET (positron emission tomography) with these devices."
"We are very pleased to have our MAPD solid-state photo detectors selected for this very important application by Professor Schmidt and his group," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. "The use of the MAPDs in the NA-61 experiments is particularly gratifying as they place Zecotek's devices at the very frontiers of particle physics. We are also very much aware that the same attributes of our unique MAPDs, which make it the optimal choice these experiments, also place our devices in the forefront of next-generation medical imaging and detection."
The MAPD solid-state photo detectors will be delivered through Zecotek Imaging Systems Pte Ltd, Zecotek's Singapore-based and wholly-owned subsidiary, and manufactured under contract by the Malaysian Institute of Microelectronic Systems and Omega Semiconductor Sdn Bhd, Malaysia.
About the NA-61 Experiments
The NA-61 experiments are being conducted at CERN, the European Organization for Nuclear Research, where the world's largest and most complex scientific instruments are used to study the basic constituents of matter - the fundamental particles. NA61 is being conducted at the Super Proton Synchrotron which studies the final states produced in interactions of various beam particles with a variety of fixed nuclear targets at extremely high energies. NA61/SHINE is the second largest experiment at CERN.
CERN, the European Organization for Nuclear Research, is one of the world's largest and most respected centres for scientific research. Its business is fundamental physics, finding out what the Universe is made of and how it works. At CERN, the world's largest and most complex scientific instruments are used to study the basic constituents of matter - the fundamental particles. By studying what happens when these particles collide, physicists learn about the laws of Nature. CERN is the home of the Large Hadron Collider (LHC). LHC experiments will address questions such as what gives matter its mass, what the invisible 96% of the Universe is made of, why nature prefers matter to antimatter and how matter evolved from the first instants of the Universe's existence. Founded in 1954, the CERN Laboratory sits astride the Franco-Swiss border near Geneva. It was one of Europe's first joint ventures and now has 20 Member States. For more information about CMS please visit http://cms.web.cern.ch/cms/Detector/WhatCMS/index.html.
Zecotek Photonics Inc. (TSX VENTURE: ZMS)(FRANKFURT: W1I) is a photonics technology company developing high-performance crystals, photo detectors, lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: imaging, lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders.
This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.